Advanced market commitments or providing financial help to firms for conducting research and development and clinical trials of Covid-19 vaccine are options that are under active consideration, the Centre said on Tuesday while reiterating that sufficient financial resources are available to procure 400-500 million doses of vaccine as and when it becomes available.
At a press conference on Tuesday, Union Health Secretary Rajesh Bhushan said that a subgroup under the National Expert Committee on Vaccine Administration for Covid-19 has already mapped the existing cold chain presently being utilised under the government's immunisation programme and has also made a projection of